The Effect of Anacetrapib on Vascular Function and Arterial Stiffness
The Effect of Anacetrapib on Vascular Function and Arterial Stiffness
There are currently no studies evaluating the effect of anacetrapib on blood vessel function
 and stiffness of the arteries. The REVEAL-Vasc trial will assess whether anacetrapib, in
 addition to atorvastatin (LDL-C lowering drug) treatment, results in greater
 endothelial-dependent vascular function and aortic stiffness in patients with established
 cardiovascular disease, compared to adding placebo.

 Participants will be asked to provide a blood sample and pulse Wave Velocity/Pulse Wave
 Analysis and Flow Mediated Dilation will be carried out to assess blood vessel function and
 stiffness of the arteries. REVEAL-Vasc is an investigator led sub-study of HPS3/TIMI 55:
 REVEAL (Randomized Evaluation of the Effects of Anacetrapib through Lipid modification): A
 large-scale, randomized placebo-controlled trial of the clinical effects of anacetrapib among
 people with established vascular disease (NCT01252953) which is coordinated by OXFORD CTSU.

 No treatment will be received on this sub-study, therefore only participants who have been
 enrolled in HPS3/TIMI55 REVEAL in which participants received anacetrapib with atorvastatin
 or placebo will be considered for this trial.
REVEAL-Vasc is an investigator led sub-study of HPS3/TIMI 55: REVEAL. Participants who
 previously enrolled on HPS3/TIMI 55: REVEAL and received treatment will be invited to
 participate in this sub-study. Participants will attend a screening and an assessment visit
 during which Pulse Wave Velocity/ Pulse Wave Analysis and Flow Mediated Dilation will be
 carried out to assess blood vessel function and stiffness. A blood sample will also be taken
 from participant to assess CRP and lipid profile. Since participants will have received
 treatment on the main trial HPS3/TIMI 55: REVEAL, no treatment will be received on this
 sub-study.
Inclusion Criteria:

 -  Participants who have been randomised into the HPS3/TIMI 55- REVEAL study
 (NCT01252953)

 Exclusion Criteria:

 -  Any concomitant condition that, at the discretion of the investigator, may affect the
 participant's ability to complete the study or study procedures

 -  Atrial fibrillation at time of assessment

 -  Inability to provide informed consent

 -  Inability to refrain from caffeine containing products for 6 hours prior to study
 visit

 -  Inability to refrain from smoking for 2 hours prior to study visit